Clinical use of polyvalent immunoglobulins

Blood Transfusion

Volumn 11, Issue SUPPL. 4, 2013, Pages

  Quinti, Isabella ^a   Pesce, Anna Maria ^a   Bonanni, Livia ^a   Rubino, Carlotta ^a   Pulvirenti, Federica ^a   Milito, Cinzia ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Indications for therapeutical usage; Inflammatory diseases; Intravenous immunoglobulin; Primary Immune Deficiencies; Subcutaneous immunoglobulin

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN G;

CHRONIC LYMPHATIC LEUKEMIA; DRUG APPROVAL; DRUG INDICATION; FOOD AND DRUG ADMINISTRATION; GUILLAIN BARRE SYNDROME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNE DEFICIENCY; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE DEFICIENCY; IMMUNOTHERAPY; MOTOR NEUROPATHY; MUCOCUTANEOUS LYMPH NODE SYNDROME; RECURRENT INFECTION; REVIEW;

HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS;

EID: 84885636042     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2013.007s     Document Type: Review

References (35)

1. Provan D, Chapel HM, Sewell WA, O'Shaughnessy D. Prescribing intravenous immunoglobulin: summary of Department of Health guidelines. BMJ 2008; 337: a1831.
2. Delforge M, Farber CM, Spath P, et al. Recommended indications for the administration of polyclonal immunoglobulin preparations. Acta Clin Belg 2011; 66: 346-60.
3. Liumbruno GM, Bennardello F, Lattanzio A, et al. Recommendations for the use of albumin and immunoglobulins. Blood Transfus 2009; 7: 216-34.
4. O'Shaughnessy D (editor). Third National Immunoglobulin Database Report (2012). Manchester: Medical Data Services and Solutions; 2013. Available at: http://www.ivig.nhs.uk/documents/Third-National-Immunoglobulin-Database-Report- 2011-2012.pdf. Accessed on 11/09/2013.
5. Orange JS, Hossny EM, Weiler CR. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006; 117: S525-53.
6. Notarangelo LD. Primary immunodeficiencies. J Allergy Clin Immunol 2010; 125: S182-94.
7. Chapel H, Lucas M, Lee M. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood 2008; 112: 277-86.
8. Quinti I, Soresina A, Guerra et al, IPINet Investigators. Effectiveness of Immunoglobulin Replacement Therapy on Clinical Outcome in Patients with Primary Antibody Deficiencies: Results from a Multicenter Prospective Cohort Study. J Clin Immunol 2011; 31: 315-22.
9. Patwa HS, Chaudhry V, Katzberg H, et al. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2012; 78: 1009-15.
10. Mackay IR, Leskovsek NV, Rose NR. The odd couple: a fresh look at autoimmunity and immunodeficiency. J Autoimmun 2010; 35: 199-205.
11. Gabriel SE, Normand SL. Getting the methods right-the foundation of patient-centered outcomes research. N. Engl J Med 2012; 367: 787-90.
12. Chapel H, Cunningham-Rundles C. Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions. Br J Haematol 2009; 145: 709-27.
13. Ochs HD, Fischer SH, Wedgwood RJ. Comparison of highdose and low-dose intravenous immunoglobulin therapy in patients with primary immunodeficiency diseases. Am J Med 1984; 76: 78-82. (Pubitemid 14126155)
14. Kaveri KS, Maddur MS, Hegde P et al. Immunoglobulins in immunodeficiencies: more than mere replacement therapy. Clinical and Experimental Immunology 2011; 164: 2-5.
15. Bonagura VR, Marchlewski R, Cox A, Rosenthal DW. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol 2008; 122: 210-2. (Pubitemid 351899076)
16. Lucas M, Hugh-Jones K, Welby A, et al. Immunomodulatory therapy to achieve maximum efficacy: doses, monitoring, compliance, and self-infusion at home. J Clin Immunol 2010; 30: S84-9.
17. Lucas M, Lee M, Lortan J, et al. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol 2010; 125: 1354-60.
18. Quinti I, Soresina A, Spadaro G. Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency. J Clin Immunol 2007; 27: 308-16. (Pubitemid 46790816)
19. Stübgen JP. A review of the use of biological agents for chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Sci 2013; 15: 1-9.
20. Winkelmann A, Zettl UK. Use of intravenous immunoglobulin in the treatment of immune-mediated demyelinating diseases of the nervous system. Curr Pharm Des 2012; 18: 4570-82.
21. Meuth SG, Kleinschnitz C. Multifocal motor neuropathy: update on clinical characteristics, pathophysiological concepts and therapeutic options. Eur Neurol 2010; 63: 193-204.
22. Bayry J, Negi VS, Kaveri SV. Intravenous immunoglobulin therapy in rheumatic diseases. Nat Rev Rheumatol 2011; 7: 349-59.
23. Gürcan HM, Ahmed AR. Efficacy of various intravenous immunoglobulin therapy protocols in autoimmune and chronic inflammatory disorders. Ann Pharmacother 2007; 41: 812-23. (Pubitemid 46752660)
24. Chen S, Dong Y, Yin Y, Krucoff MW. Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis. Heart 2013; 99: 76-82.
25. Neunert CE, Buchanan GR, Imbach P, et al; Intercontinental Cooperative ITP Study Group Registry II Participants. Bleeding manifestations and management of children with persistent and chronic immune thrombocytopenia: data from the Intercontinental Cooperative ITP Study Group (ICIS). Blood 2013; 121: 4457-62
26. De Mattia D, Del Vecchio GC, Russo G, et al; AIEOP-ITP Study Group. Management of chronic childhood immune thrombocytopenic purpura: AIEOP consensus guidelines. Acta Haematol 2010; 123: 96-109.
27. Collins PW, Newland AC. Treatment modalities of autoimmune blood disorders. Semin Hematol 1992; 29: 64-74
28. Raanani P, Gafter-Gvili A, Paul M, et al. Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis. Leuk Lymphoma 2009; 50: 764-72.
29. Gürcan HM, Jeph S, Ahmed AR. Intravenous immunoglobulin therapy in autoimmune mucocutaneous blistering diseases: a review of the evidence for its efficacy and safety. Am J Clin Dermatol 2010; 11: 315-26.
30. Enk A. Guidelines on the use of high-dose intravenous immunoglobulin in dermatology. Eur J Dermatol 2009; 19: 90-8.
31. Huang YC, Li YC, Chen TJ. The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis. Br J Dermatol 2012; 167: 424-32.
32. Bartel G, Schwaiger E, Böhmig GA. Prevention and treatment of alloantibody-mediated kidney transplant rejection. Transpl Int 2011; 24: 1142-55.
33. Baxley A, Akhtari M. Hematologic toxicities associated with intravenous immunoglobulin therapy. International Immunopharmacology 2011; 11: 1663-7.
34. Pierce LR, Jain N. Risks associated with the use of intravenous immunoglobulin. Transfus Med Rev 2003; 17: 241-51. (Pubitemid 37310931)
35. Orange JS, Hossney EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006; 117 (Suppl): S525-53.